Jiyeon Park

Jiyeon Park

Auto-generated profile, based on publicly available information

Jiyeon Park

Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JPJiyeon Park
Jiyeon Park
KHKi Young Huh
Ki Young Huh
WCWoo Kyung Chung
Woo Kyung Chung
KYKyung-Sang Yu
Kyung-Sang Yu
Park J, et al. Transl Clin Pharmacol. 2024 Mar;32(1):41-51. https://doi.org/10.12793/tcp.2024.32.e2

8 September 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
KHKi Young Huh
Ki Young Huh
WCWoo Kyung Chung
Woo Kyung Chung
JPJiyeon Park
Jiyeon Park
SLSeungHwan Lee
SeungHwan Lee
MKMin-Gul Kim
Min-Gul Kim
KYKyung‐Sang Yu
Kyung‐Sang Yu
Decentralized clinical trials (DCTs) leverage digital technologies to reduce dependency on study sites and intermediaries. DCT should be balanced with accessibility and data reliability while meeting regulatory requirements. Here, we conducted a pilot study for functional constipation symptoms to investigate the feasibility of DCT. The study was an open, fully remote, randomized clinical trial in participants who had functional constipation symptoms. Electronic consent was obtained remotely, and study volunteers were screened through web‐based questionnaires. Subjects were randomized to either receive Lactobacillus and vitamin C supplements or vitamin C alone in a 1:1 ratio, which were delivered directly to subjects. Subjects kept track of bowel diaries daily during the 1‐week baseline and 2‐week treatment period using mobile applications. Bowel symptoms and the validity of the records were descriptively evaluated. A total of 30 subjects were randomized and completed the study. A total of 26.7% of subjects resided outside of the metropolitan area. Two‐week Lactobacillus treatments increased the number of defecations (+0.80 vs. +0.46 times per week) and decreased the defecation time (−3.94 h vs. −1.62 h) compared to the comparator group. Overall, 67.1% of bowel diary records were completed in accordance with the schedule whereas 32.9% were not. Implementation of DCTs can facilitate geographic accessibility but should be guaranteed for data reliability. Prompt detection of errors and response using objective metrics would be required.

1 January 2024 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
WCWoo Kyung Chung
Woo Kyung Chung
KHKi Young Huh
Ki Young Huh
JPJiyeon Park
Jiyeon Park
JOJaeseong Oh
Jaeseong Oh
KYKyung-Sang Yu
Kyung-Sang Yu
Chung WK, et al. Transl Clin Pharmacol. 2024 Mar;32(1):30-40. https://doi.org/10.12793/tcp.2024.32.e1

2 March 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
KHKi Young Huh
Ki Young Huh
ISIldae Song
Ildae Song
YKYoonjin Kim
Yoonjin Kim
JPJiyeon Park
Jiyeon Park
HRHyunwook Ryu
Hyunwook Ryu
SLSeungHwan Lee
SeungHwan Lee
Despite interest in clinical trials with decentralized elements (DCTs), analysis of their trends in trial registries is lacking due to heterogeneous designs and unstandardized terms. We explored Llama 3, an open‐source large language model, to efficiently evaluate these trends. Trial data were sourced from Aggregate Analysis of ClinicalTrials.gov, focusing on drug trials conducted between 2018 and 2023. We utilized three Llama 3 models with a different number of parameters: 8b (model 1), fine‐tuned 8b (model 2) with curated data, and 70b (model 3). Prompt engineering enabled sophisticated tasks such as classification of DCTs with explanations and extracting decentralized elements. Model performance, evaluated on a 3‐month exploratory test dataset, demonstrated that sensitivity could be improved after fine‐tuning from 0.0357 to 0.5385. Low positive predictive value in the fine‐tuned model 2 could be improved by focusing on trials with DCT‐associated expressions from 0.5385 to 0.9167. However, the extraction of decentralized elements was only properly performed by model 3, which had a larger number of parameters. Based on the results, we screened the entire 6‐year dataset after applying DCT‐associated expressions. After the subsequent application of models 2 and 3, we identified 692 DCTs. We found that a total of 213 trials were classified as phase 2, followed by 162 phase 4 trials, 112 phase 3 trials, and 92 phase 1 trials. In conclusion, our study demonstrated the potential of large language models for analyzing clinical trial information not structured in a machine‐readable format. Managing potential biases during model application is crucial.

1 April 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
JPJiyeon Park
Jiyeon Park
SLSeungHwan Lee
SeungHwan Lee
JCJae-Yong Chung
Jae-Yong Chung
SYSungil Yun
Sungil Yun
HPHan-Oh Park
Han-Oh Park
IJInJin Jang
InJin Jang
SRN001 is a small interfering RNA (siRNA) drug targeting amphiregulin. It was developed using a novel SAMiRNA® platform, in which the siRNAs are protected within a self-assembled micelle. This platform eliminates the need for additional excipients to reduce unintended immune reactions. Amphiregulin plays a critical role in tissue repair and immune modulation. By silencing it, SRN001 is expected to be a therapeutic option for various pathologically fibrotic and cancerous diseases. This study aimed to evaluate safety and pharmacokinetics (PK) of SRN001 in humans for the first time. A randomized, double-blind, placebo-controlled, single ascending dose, Phase 1 trial was conducted (NCT05984992). Participants randomly received a single intravenous dose of SRN001 (15, 45, 135, or 210 mg) or placebo. Safety was assessed with vital signs, clinical laboratory tests, electrocardiograms, and inflammatory cytokine assays (IL-1β, IL-6, IFN-γ, and TNF-α). Serial blood samples were collected until 168 hours post-dose to quantify plasma antisense siRNA concentrations. Anti-drug antibodies (ADAs) were measured at pre-dose, 15 days, and 29 days post-dose. Among 25 participants, SRN001 was generally well tolerated. Unlike other approved siRNA drugs, no systemic symptoms or cytokine elevation suggestive of infusion-related reactions (IRRs) were observed in any subjects receiving SRN001, even without premedication. SRN001 exhibited dose-proportional exposure, with the average AUCinf of 1.35 ug·hour/mL in the 15 mg dose group, achieving the therapeutic exposure in preclinical studies. The average plasma half-life was 0.48 hours. No ADAs were detected. A single IV administration of SRN001 demonstrated a favorable safety profile and dose-proportional PK in this small first-in-human phase 1 clinical trial. By minimizing the need for excipients, the SAMiRNA platform is anticipated to facilitate the development of safer siRNA drugs in the future. Therapeutic potential of SRN001 will be explored in subsequent clinical trials.

3 September 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
JPJiyeon Park
Jiyeon Park
KHKi Young Huh
Ki Young Huh
JCJae-Yong Chung
Jae-Yong Chung
KYKyung‐Sang Yu
Kyung‐Sang Yu
Decentralized elements enhanced patient centricity by shifting trial‐related activities outside traditional trial sites. On the other hand, remote data collection poses potential risks to data integrity. Although these two are critical aspects of decentralized elements, methodologies for assessing them remain limited. We proposed a method to measure patient centricity by subtracting the participant's self‐rated burden for trial‐related procedures with decentralized elements from their estimated burden under the traditional approach. Additionally, we introduced an analytical framework to assess data integrity by considering the accurate performance rate, the sources of errors, and their cascading consequences. The feasibility and applicability of these methodologies were explored in a pilot clinical trial on mastic gum. Patient centricity was highest in wearable device‐based drug adherence monitoring (4.30) and lowest in remote consent submission (1.80). For most trial‐related procedures, patient centricity tended to be higher when participant engagement increased. However, blood sample collection recorded higher patient centricity when participants visited a nearby local hospital for nurse assistance (2.55) compared to the estimated burden of using a self‐kit at home (2.35). Data integrity was lowest in wearable device‐based drug adherence monitoring (88.6%), and the errors were attributable to the device being left behind, insufficient proficiency, broken WiFi connection, and depleted battery. Data integrity was second lowest in self‐kit‐based stool specimen collection (90.0%), and the errors led to successive delays in specimen delivery and microbiome analysis. The proposed methodologies will provide a foundation for assessing and predicting the impact of decentralized elements on clinical trials. Trial Registration: ClinicalTrials.gov identifier: NCT06005805